Werewolf Therapeutics, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: -100.0%
EBITDA: +25.0%
EBIT: +30.6%
EPS: +26.2%
Free cash flow: +13.4%
Operating cash flow: +13.2%

Forward estimates

Revenue: —
EBITDA: —
EPS: -44.9%

Three-year CAGR

Revenue: -100.0%
EBITDA: +15.8%
EBIT: +17.6%
Net income: +13.7%
EPS: +19.0%
Free cash flow: -6.8%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.